RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Revenue growth (%)

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$3.9B
P/E ratio
SummaryFinancials
Period EndRevenue growth (%) YoY (%)
Dec 31, 202427.3-182.44%
Dec 31, 2023-33.1+13.36%
Dec 31, 2022-29.2-159.99%
Dec 31, 202148.7-11.50%
Dec 31, 202055-205.39%
Dec 31, 2019-52.2-166.71%
Dec 31, 201878.2+165.30%
Dec 31, 201729.5-42.79%
Dec 31, 201651.5+350.83%
Dec 31, 201511.4-64.03%
Dec 31, 201431.8-43.27%
Dec 31, 201356+1144.89%
Dec 31, 20124.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)